Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garetosmab in Healthy Participants With Obesity
NCT06970405Phase 1Withdrawn
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2025
- Primary completion
- Jun 2026
01
Overview
Phase 1, randomised, double-blind trial of garetosmab in obesity, sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events and Severity of treatment-emergent adverse events. Planned start May 2025; status: withdrawn.
02
Drugs
garetosmab
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06970405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970405.